FDA approves generic HIV prevention shot to widen access

· Health · United States

The FDA has approved a generic version of an HIV prevention shot, STAT reports, a key step toward widening access for dozens of lower-income countries. The approval covers a long-acting injectable form of pre-exposure prophylaxis, which is used to reduce the risk of HIV infection. Generic competition is expected to lower the price of a product that has been costly and logistically demanding to deliver at scale. The report frames the decision as significant for global access, because many lower-income countries rely on generic suppliers and donor-funded procurement programs. Specifics of the manufacturer, pricing or launch timing were not included.

Why it matters：Cheaper generic versions of long-acting HIV prevention could shift global procurement and expand prophylaxis in lower-income markets, a test of how fast generic competition follows branded approval.

Key points

  • The shot is a long-acting HIV prevention injectable.
  • The approval is aimed at widening access in dozens of lower-income countries.

Sources (original reporting)

More stories from this day